NCT05196373撤回1 期
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of STP705 Administered as Intrascar Injection in Adult Patients With Hypertrophic Scars
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- Sirnaomics
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Concentration of siRNA-TGF-B1 and siRNA-COX-2 in serum
研究概览
简要总结
Adult patients with hypertrophic scars 30 Subjects in Dose Escalation 20 Subjects in Dose Expansion Intrascar injection of STP705 weekly for 4 weeks
详细描述
An open label study design to evaluate the preliminary efficacy of STP705 in adult patients with hypertrophic scars.
The study is divided into 2 stages:
1. Dose Escalation: 30 subjects to be enrolled in this stage with a total of 6 dose groups.
3 subjects will be enrolled in 10ug and 20ug groups and 6 subjects in the subsequent groups of 40ug, 60ug, 80u and 100ug.
2. Dose Expansion:1-2 dose groups will be selected and 20 subjects will be enrolled in each group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female adult ≥ 18 and ≤ 45 years old at the time of signing the ICF,
- •Diagnosed with hypertrophic scars, with all the following characteristics:
- •Linear hypertrophic scar, with a width of 0.3-1.0 cm and a length of ≥10 cm;
- •Scars with any of the following characteristics: redness or purpleness, stiffness, rough surface, significant swelling, visible dilated capillaries on the surface, and possibly accompanied by pain or itching;
- •The course of the disease is 6 to 24 months (inclusive);
- •Scars are not located on the face, front of the neck, feet, hands, knees, elbows or any joints;
- •The examination during the screening period must meet the following criteria: medical history, physical examination (excluding hypertrophic scar), 12-lead ECG, vital signs, laboratory examinations are judged by the investigator to meet the requirements, and no clinically significant abnormalities were observed;
- •Subjects of childbearing potential (male or female) must take effective medical contraceptive measures during the study and within 6 months after the end of administration;
- •Subjects voluntarily participate in this clinical trial and sign the ICF, can understand and comply with the study procedures, and complete the entire study as specified by the protocol.
排除标准
- •Diagnosed with keloid or burn scar;
- •Positive in hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency virus (HIV), or syphilis antibody tests;
- •Medication history of corticosteroids use (including inhaled steroids, triamcinolone acetonide, etc.) and COX-2 inhibitors within 3 months before the first injection of the study (if 5 times the half-life is longer than 3 months, then 5 times the half-life will prevail);
- •Impaired immune function (such as cancer, or other diseases that affect the basic immune responses);
- •Concomitant diseases that is uncontrolled or poorly controlled or may affect the study, including clinically important cardiovascular, lung, kidney, endocrine, liver, nerve, mental, immune, gastrointestinal, blood, urogenital, skeletal or metabolic disorders at the investigator's discretion;
- •Known to be allergic to STP705 or any components of its prescription;
- •Having difficulty in venous blood collection, or having a history of needle fainting or blood fainting;
- •Infection or trauma in the site to be treated;
- •Pregnant and lactating women;
- •Participated in other clinical studies and received treatment within 3 months before the first injection;
- •Blood donation or blood loss ≥400 mL within 3 months before the first injection (except for female blood loss during menstrual period), or planning to donate blood or blood components during the study period or within 3 months after the end of the study;
- •History of drug abuse/dependence or drug history or positive in drug abuse screening (screening items can include: morphine, tetrahydrocannabinol acid, methamphetamine, methylenedioxy methanphetamine, ketamine and cocaine) within 1 year before the first injection;
- •Medication history of any drugs (including prescription drugs, over-the-counter drugs, Chinese herbal medicines, etc.) or health care products within 14 days before the first injection;
- •Vaccinated with live vaccines within 4 weeks before the first injection or planning to receive live vaccines within 4 weeks after the last dose. Live vaccines include but not limited to: measles, mumps, rubella, chickenpox, yellow fever, rabies, Bacillus Calmette-Guerin, typhoid fever, COVID-19 live vaccines, etc.;
- •Any surgical, medical or laboratory pathophysiological conditions that may interfere with the safety, distribution, metabolism or excretion of the investigational drug at the discretion of the investigator;
- •Unable to communicate or cooperate with medical staff due to neurological, mental disorders or language/ verbal communication issues;
- •Other situations not suitable for participation in the study as judged by the investigator.
研究组 & 干预措施
Part 1: Group 4
Experimental
60ug Intrascar injection
干预措施: STP705 (Drug)
Part 1: Group 3
Experimental
40ug Intrascar injection
干预措施: STP705 (Drug)
Part 1: Group 6
Experimental
100ug Intrascar injection
干预措施: STP705 (Drug)
Part 1: Group 2
Experimental
20ug Intrascar injection
干预措施: STP705 (Drug)
Part 1: Group 1
Experimental
10ug Intrascar injection
干预措施: STP705 (Drug)
Part 1: Group 5
Experimental
80ug Intrascar injection
干预措施: STP705 (Drug)
结局指标
主要结局
Concentration of siRNA-TGF-B1 and siRNA-COX-2 in serum
时间窗: 7 weeks
siRNA-TGF-B1 and siRNA-COX-2 and HKP will be calculated
次要结局
- Change of the scar from baseline using Observer Scar Assessment Scale(7 weeks)
- Change of the scar from baseline using Patient scale(7 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary CancerGastric CancerBiliary CancerPancreatic CancerColorectal CancerNCT02908451AbGenomics B.V Taiwan Branch39
已完成
1 期
PDM08 Clinical Trial in Advanced Solid TumorsMalignant Solid TumoursNCT01380249Prodimed S.A.22
招募中
1 期
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast CancerAdvanced or Metastatic Breast CancerNCT05187832Kind Pharmaceuticals LLC61
已完成
1 期
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid TumorsAdvanced CancerMetastatic CancerNeoplasmsNeoplasm MetastasisNeoplastic ProcessesPathologic ProcessesNCT03510104Meryx, Inc.42
已完成
1 期
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid TumorsAdvanced Solid TumorNCT05155722Bio-Thera Solutions59